BioSpace News Archive

Neuromod Devices Ltd, the Irish medical device company specialising in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc., a subsidiary headquartered in Oak Brook, Illinois.

The Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis research, education, and advocacy organization, today announced the appointment of Joseph Lasky, MD, to the position of Chief Medical Officer.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors against SARS-CoV-2 and all current and emerging variants of concern (VOCs).

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced that its management team will present at the following upcoming investor conferences:

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences:

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), and Innovent Biologics, Inc. (HKEX: 01801), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), today announced that members of the management team will participate in a virtual fireside chat at the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its second quarter financial results for the quarter ended June 30, 2021.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at three upcoming virtual investor conferences: